The major indexes hit fresh highs, buoyed by Salesforce and mostly positive tech earnings. Bitcoin briefly topped $100,000.

Despite their potential benefits, the rise of weight loss drugs like Ozempic and Wegovy has sparked important conversations about body image, weight loss expectations, and the broader implications of ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

The trial, known as SURMOUNT-5, found that participants using Zepbound lost an average of 20.2% of their body weight, while those on Wegovy lost 13.7%. This marks a 47% difference in weight loss ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...

If you want to take Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight management, you might also be exploring telemedicine and the convenience of getting a ...

Catalent is an attractive buyout target for Novo Holdings — which owns 77% of the voting shares in the drugmaker — because it is currently a subcontractor that helps manufacture Wegovy ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...